In the Claims:

Please amend the claims by replacing all prior versions of the claims pursuant to 37 C.F.R. §1.121 as modified by 68 Fed. Reg. 38611 (June 30, 2003) as follows:

1-4. (Canceled)

5. (Previously Presented) An antisense oligonucleotide comprising nucleotide sequence A, B, C, D, E, F, G, H, I, J, K, L, or M (SEQ ID NOS: 1-13), respectively, wherein the oligonucleotide is conjugated to a peptide.

6-8. (Canceled)

9. (Previously Presented) An antisense oligonucleotide comprising nucleotide sequence A, B, C, D, E, F, G, H, I, J, K, L, or M (SEQ ID NOS: 1-13), respectively, wherein one or more of the oligonucleotide's sugars contain an -OMe group at their 2' position.--.

10-16. (Canceled)

17. (Withdrawn) A method of treating cancer, comprising introducing into a tumor cell an effective amount of an antisense oligonucleotide comprising nucleotide sequence A, B, C, D, E, F, G, H, I, J, K, L, or M (SEQ ID NOS: 1-13), respectively, wherein the oligonucleotide comprises one or more bases with a C-5 propynyl pyrimidine modification, thereby reducing the levels of bcl-2 protein produced and treating cancer.

18. (Withdrawn) The method of claim 17, wherein the cancer is

epithelial cancer.

19. (Withdrawn) The method of claim 18, wherein the epithelial cancer is prostate cancer.

20. (Withdrawn) The method of claim 18, wherein the epithelial cancer is lung cancer.

21. (Withdrawn) The method of claim 18, wherein the epithelial cancer is bladder cancer.

22. (Withdrawn) The method of claim 17, wherein the introducing comprises using a lipid as a delivery agent.

23. (Withdrawn) The method of claim 17, wherein the introducing comprises using porphyrin or lipofectin as a delivery agent.

24. (Withdrawn) The method of claim 17, wherein the effective amount is between 0.1 μM and 10 μM.

25. (Withdrawn) The method of claim 17, wherein the effective amount is between 0.1 μM and 4 μM.

26. (Withdrawn) The method of claim 17, wherein the effective amount is between 0.4 μM and 1 μM.

27. (Withdrawn) A method of treating cancer, comprising introducing into a tumor cell an effective amount of an antisense oligonucleotide comprising nucleotide sequence A, B, C, D, E, F, G, H, I, J, K, L, or M (SEQ ID NOS: 1-13), respectively, thereby reducing the levels of bcl-xL protein produced and treating cancer.--

28. (Withdrawn) The method of claim 27, wherein the cancer is epithelial cancer.

29. (Withdrawn) The method of claim 28, wherein the epithelial cancer is prostate cancer.

30. (Withdrawn)The method of claim 28, wherein the epithelial cancer is lung cancer.

31. (Withdrawn) The method of claim 28, wherein the epithelial cancer is bladder cancer.

32. (Withdrawn) The method of claim 27, wherein the introducing comprises using a lipid as a delivery agent.

33. (Withdrawn) The method of claim 27, wherein the introducing comprises using porphyrin or lipofectin as a delivery agent.

34. (Withdrawn) The method of claim 27, wherein the effective amount is between 0.1 μM and 10 μM.

35. (Withdrawn) The method of claim 27, wherein the effective amount is between 0.1 μM and 4 μM.

36. (Withdrawn) The method of claim 27, wherein the effective amount is between 0.4 μM and 1 μM.

37. (Withdrawn) A method of promoting the regression of vascular lesions, comprising introducing into a vascular cell an amount of an antisense oligonucleotide comprising nucleotide sequence A, B, C, D, E, F, G, H, I, J, K, L, or

M (SEQ ID NOS: 1-13), respectively, effective to reduce the levels of bcl-xL protein produced, thereby promoting the regression of vascular lesions.

38. (Withdrawn) The method of claim 37, wherein the introducing comprises using a lipid as a delivery agent.

39. (Withdrawn) The method of claim 37, wherein the introducing comprises using porphyrin or lipofectin as a delivery agent.

40. (Withdrawn) The method of claim 37, wherein the effective amount is between 0.1 μM and 4 μM.

41. (Withdrawn) The method of claim 37, wherein the effective amount is between 0.4 μM and 1 μM.

42. (Canceled)

43. (Previously Presented) A pharmaceutical composition comprising an effective amount of an antisense oligonucleotide or analog thereof of claim ~~3~~ 5 or 9 and a pharmaceutically acceptable carrier, wherein the effective amount is between 0.1 μM and 10 μM.

44-47. (Canceled).